8-K: Cassava Reports Q3 2025, Advances Epilepsy Drug

Cassava Sciences reported a reduced net loss in Q3 2025, with $106.1 million cash, and is progressing simufilam for TSC-related epilepsy towards a H1 2026 clinical study.

Summary

• Cassava Sciences reported a net loss of $10.8 million, or $0.22 per share, for the third quarter ended September 30, 2025, a significant improvement from a net loss of $27.9 million, or $0.58 per share, for the same period in 2024.
• The company held $106.1 million in cash and cash equivalents with no debt as of September 30, 2025, down from $128.6 million at December 31, 2024.
• Net cash used in operations was $22.5 million during the first nine months of 2025.
• Cash at year-end 2025 is estimated to be in the range of $92 to $96 million, including an incremental cash use of $10 to $14 million expected in Q4 2025, which is a downward revision from previous guidance for net cash use in operations for the second half of 2025.
• Simufilam is advancing as a potential treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy, with a proof-of-concept clinical study expected to begin in the first half of 2026.
• Preclinical data from mouse models of TSC-related epilepsy showed simufilam alleviated neuronal abnormalities and reduced seizure frequency by 60% compared to vehicle, and attenuated the progression of seizure activity with a statistically significant correlation between dose and number of seizures.
• Research and development (R&D) expenses decreased by 78% to $4.0 million in Q3 2025 from $17.7 million in Q3 2024, primarily due to the completion of the Alzheimer's disease development program in Q2 2025.
• General and administrative (G&A) expenses decreased by 39% to $7.9 million in Q3 2025 from $12.9 million in Q3 2024, mainly due to a $2.5 million decrease in legal-related costs and a $1.3 million decrease in compensation costs.
• The company appointed Joseph Hulihan, MD, MSHP, as Chief Medical Officer and Ms. Dawn C. Bir as an Independent Director to its Board.

Sentiment

Score: 7

Explanation: The sentiment is cautiously positive. Financial results show a significant reduction in net loss and expenses, indicating improved operational efficiency and a strong cash position. The strategic pivot to TSC-related epilepsy with promising preclinical data and a clear timeline for a clinical study in H1 2026 is a strong positive. However, the downward revision of cash guidance and the unclear timing of a significant litigation settlement introduce some uncertainty.

Positives

• Net loss significantly reduced to $10.8 million in Q3 2025 from $27.9 million in Q3 2024, indicating improved financial efficiency.
• Strong cash and cash equivalents position of $106.1 million as of September 30, 2025, with no debt, expected to support operations into 2027.
• Positive preclinical data for simufilam in TSC-related epilepsy mouse models, showing a 60% reduction in seizure frequency and attenuated seizure progression.
• Clear strategic focus on TSC-related epilepsy with a planned proof-of-concept clinical study in H1 2026.
• Significant reduction in R&D expenses (78% decrease) due to the completion of the Alzheimer's program, allowing for resource reallocation.
• Reduction in G&A expenses (39% decrease) driven by lower legal and compensation costs.
• Strengthened leadership with the appointment of Joseph Hulihan as CMO and Dawn C. Bir to the Board of Directors, bringing relevant expertise.

Negatives

• Downward revision of previous guidance for net cash use in operations for the second half of 2025, indicating higher cash burn than initially projected.
• The timing of the $31.25 million estimated loss contingency related to a potential securities litigation settlement remains unclear, creating financial uncertainty.

Risks

• The ability to advance preclinical studies related to TSC-related epilepsy and other potential indications is uncertain.
• There is a risk in successfully carrying out the company's obligations under the Yale License Agreement.
• The ability to initiate an initial proof-of-concept study of simufilam in TSC-related epilepsy is not guaranteed.
• Drug discovery and development inherently involve significant risks, uncertainties, and assumptions.
• Clinical results from earlier-stage clinical trials or preclinical studies may not be indicative of future results from later-stage or larger-scale clinical trials and do not ensure regulatory approval.
• All pharmaceutical assets under development are investigational product candidates and have not been approved for use in any medical indication by any regulatory authority.
• The safety, efficacy, or other desirable attributes of product candidates have not been established in any patient population.
• Drug discovery and development activities are long, complex, costly, and involve a high degree of risk, potentially leading to a total loss of investment for shareholders.

Future Outlook

The company expects its current cash and cash equivalents of $106.1 million to support operations into 2027. It estimates year-end 2025 cash to be between $92 and $96 million, with an additional $10 to $14 million in cash use anticipated in Q4 2025. A proof-of-concept clinical study for simufilam in TSC-related epilepsy is planned to commence in the first half of 2026, with preclinical data to be presented at an upcoming scientific conference and publication. The timing of a potential $31.25 million securities litigation settlement payment remains unclear.

Management Comments

• "2025 has been a year of significant progress for Cassava. We launched a program for simufilam focused on TSC-related epilepsy, building on the results of two sophisticated animal studies that support simufilam's potential use as a first-in-class treatment. We enhanced our development capabilities with top-tier experts in neuroscience and medicine, and we expanded our Board to strategically guide this important new initiative."
• "We are excited to be working with the TSC Alliance and key opinion leaders in the field of TSC to create a proof-of-concept study which we intend to initiate in the first half of 2026."

Industry Context

This announcement positions Cassava Sciences within the niche but high-need area of rare neurological disorders, specifically Tuberous Sclerosis Complex (TSC)-related epilepsy. TSC affects approximately 50,000 people in the US, with 80-90% experiencing seizures, and two-thirds having refractory epilepsy. Current therapies, including antiepileptic drugs and mTOR inhibitors, are noted as not fully effective and associated with serious adverse events, indicating a significant unmet medical need. Cassava's focus on simufilam, an investigational oral small molecule believed to modulate filamin A protein activity, aims to address this gap with a potentially first-in-class treatment, leveraging preclinical success and collaborations with academic institutions and patient advocacy groups like the TSC Alliance.

Comparison to Industry Standards

• The filing highlights that current therapies for TSC-related epilepsy, including antiepileptic drugs and mTOR inhibitors, are not fully effective and are associated with serious adverse events. This indicates a significant unmet medical need within the industry for more efficacious and tolerable treatments.
• Simufilam's preclinical results, showing a 60% reduction in seizure frequency in a mouse model, suggest a potentially strong efficacy profile compared to the limitations of existing treatments, though these are early-stage findings and not directly comparable to human clinical trial outcomes of approved drugs.
• The collaboration with the TSC Alliance and the TSC Preclinical Consortium aligns with industry best practices for rare disease drug development, emphasizing patient advocacy and specialized research networks to accelerate therapeutic innovation.

Management Changes

Corporate Governance

Legal Proceedings

• The company maintains a $31.25 million estimated loss contingency related to a potential settlement of certain securities litigation recorded in Q2 2025. The timing of this potential settlement payment is unclear.

Stakeholder Impact

• **Shareholders:** Positive impact from reduced net loss and expenses, strong cash position, and clear strategic direction for a new drug program. However, the downward revision of cash guidance and unclear litigation settlement timing introduce some financial uncertainty.
• **Patients (TSC-related epilepsy):** Potential positive impact from the advancement of simufilam as a novel, investigational treatment, addressing an unmet medical need where current therapies are not fully effective.
• **Employees:** Management changes with new appointments could bring fresh perspectives and expertise, potentially impacting team dynamics and strategic execution.
• **Regulatory Authorities:** The company is developing a regulatory strategy for the planned proof-of-concept study, indicating ongoing engagement with regulatory processes for drug approval.

Next Steps

• Initiate a proof-of-concept clinical study for simufilam in TSC-related epilepsy in the first half of 2026.
• Present preclinical data and analyses in an upcoming scientific conference and publication.
• Continue preparations for the regulatory strategy for the TSC-related epilepsy program.

Key Dates

Recommendation

While Cassava Sciences demonstrated improved financial performance with a significantly reduced net loss and expenses, and has a strong cash position, the core business remains high-risk, early-stage drug development. The pivot to TSC-related epilepsy with promising preclinical data is a positive strategic move, but the success of clinical trials is highly uncertain. The downward revision of cash guidance and the unresolved securities litigation settlement add elements of financial risk. A 'hold' recommendation reflects the speculative nature of the investment, acknowledging both the positive operational efficiencies and strategic focus, alongside the inherent risks of biotech R&D and financial uncertainties.

Keywords

Cassava Sciences, SAVA, biotechnology, TSC-related epilepsy, simufilam, Q3 2025 financial results, CNS disorders, drug development, preclinical data, corporate governance, clinical study, rare disease